The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carries risks due to high concentration and regulatory challenges. Short-term catalysts include earnings momentum, FDA approvals, and sector mergers. Trading at a P/E of 16.11x after a rally, IHE is rated HOLD due to patent and concentration risks.
Five dividend stocks—Procter & Gamble, Johnson & Johnson, Coca-Cola, Colgate-Palmolive, and PepsiCo—have consistently raised their dividends through every U.S. recession since at least 1963. These companies demonstrated resilience during major downtu...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
In 2026, JPMorgan's Nasdaq-focused ETF (JEPQ) has delivered significantly higher monthly income distributions than its S&P 500-based sibling (JEPI), driven by the greater volatility and option premiums of the tech-heavy Nasdaq index. JEPI offers broa...
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Johnson & Johnson announced new pivotal Phase 3 clinical data for CAPLYTA (lumateperone) in treating bipolar mania, alongside additional findings in bipolar depression and major depressive disorder. The data, presented at the 2026 Psych Congress, hig...
